Full Text Available
Note: Clicking the button above will open the full text document at the original institutional repository in a new window.
Asciminib Provides Better Efficacy and Favorable Safety and Tolerability Against Investigator‐Selected Tyrosine Kinase Inhibitors in East Asian Patients With Newly Diagnosed Chronic Myeloid Leukemia: Results From a Subgroup Analysis of the Pivotal ASC4FIRST Study
Saved in:
| Published in: | Cancer Medicine |
|---|---|
| Format: | Online Article RSS Article |
| Published: |
2026
|
| Subjects: | |
| Tags: |
No Tags, Be the first to tag this record!
|
| _version_ | 1869028931216080896 |
|---|---|
| collection | WordPress RSS FRELIP Feed Integration |
| container_title | Cancer Medicine |
| description | |
| discipline_display | Oncology |
| discipline_facet | Oncology |
| format | Online Article RSS Article |
| genre | Journal Article |
| id | rss_article:95838 |
| institution | FRELIP |
| journal_source_facet | Cancer Medicine |
| last_indexed | 2026-06-26T03:34:48.312Z |
| publishDate | 2026 |
| publishDateSort | 2026 |
| record_format | rss_article |
| spellingShingle | Asciminib Provides Better Efficacy and Favorable Safety and Tolerability Against Investigator‐Selected Tyrosine Kinase Inhibitors in East Asian Patients With Newly Diagnosed Chronic Myeloid Leukemia: Results From a Subgroup Analysis of the Pivotal ASC4FIRST Study Oncology General Oncology |
| sub_discipline_display | General |
| sub_discipline_facet | General |
| subject_display | Oncology General Oncology |
| subject_facet | Oncology General Oncology |
| title | Asciminib Provides Better Efficacy and Favorable Safety and Tolerability Against Investigator‐Selected Tyrosine Kinase Inhibitors in East Asian Patients With Newly Diagnosed Chronic Myeloid Leukemia: Results From a Subgroup Analysis of the Pivotal ASC4FIRST Study |
| title_alt | Asciminib proporciona mejor eficacia y seguridad y tolerabilidad favorables frente a inhibidores de tirosina quinasa seleccionados por el investigador en pacientes de Asia Oriental con leucemia mieloide crónica recién diagnosticada: resultados de un análisis de subgrupo del estudio pivotal ASC4FIRST L'Asciminib offre une meilleure efficacité et une sécurité et tolérabilité favorables par rapport aux inhibiteurs de tyrosine kinase sélectionnés par l'investigateur chez les patients est-asiatiques atteints de leucémie myéloïde chronique nouvellement diagnostiquée : résultats d'une analyse de sous-groupe de l'étude pivot ASC4FIRST Asciminibe Proporciona Melhor Eficácia e Segurança e Tolerabilidade Favoráveis em Relação aos Inibidores de Tirosina Quinase Selecionados pelo Investigador em Pacientes do Leste Asiático com Leucemia Mieloide Crônica Recentemente Diagnosticada: Resultados de uma Análise de Subgrupo do Estudo Fundamental ASC4FIRST |
| title_auth | Asciminib Provides Better Efficacy and Favorable Safety and Tolerability Against Investigator‐Selected Tyrosine Kinase Inhibitors in East Asian Patients With Newly Diagnosed Chronic Myeloid Leukemia: Results From a Subgroup Analysis of the Pivotal ASC4FIRST Study |
| title_es_txt | Asciminib proporciona mejor eficacia y seguridad y tolerabilidad favorables frente a inhibidores de tirosina quinasa seleccionados por el investigador en pacientes de Asia Oriental con leucemia mieloide crónica recién diagnosticada: resultados de un análisis de subgrupo del estudio pivotal ASC4FIRST |
| title_fr_txt | L'Asciminib offre une meilleure efficacité et une sécurité et tolérabilité favorables par rapport aux inhibiteurs de tyrosine kinase sélectionnés par l'investigateur chez les patients est-asiatiques atteints de leucémie myéloïde chronique nouvellement diagnostiquée : résultats d'une analyse de sous-groupe de l'étude pivot ASC4FIRST |
| title_full | Asciminib Provides Better Efficacy and Favorable Safety and Tolerability Against Investigator‐Selected Tyrosine Kinase Inhibitors in East Asian Patients With Newly Diagnosed Chronic Myeloid Leukemia: Results From a Subgroup Analysis of the Pivotal ASC4FIRST Study |
| title_fullStr | Asciminib Provides Better Efficacy and Favorable Safety and Tolerability Against Investigator‐Selected Tyrosine Kinase Inhibitors in East Asian Patients With Newly Diagnosed Chronic Myeloid Leukemia: Results From a Subgroup Analysis of the Pivotal ASC4FIRST Study |
| title_full_unstemmed | Asciminib Provides Better Efficacy and Favorable Safety and Tolerability Against Investigator‐Selected Tyrosine Kinase Inhibitors in East Asian Patients With Newly Diagnosed Chronic Myeloid Leukemia: Results From a Subgroup Analysis of the Pivotal ASC4FIRST Study |
| title_pt_txt | Asciminibe Proporciona Melhor Eficácia e Segurança e Tolerabilidade Favoráveis em Relação aos Inibidores de Tirosina Quinase Selecionados pelo Investigador em Pacientes do Leste Asiático com Leucemia Mieloide Crônica Recentemente Diagnosticada: Resultados de uma Análise de Subgrupo do Estudo Fundamental ASC4FIRST |
| title_short | Asciminib Provides Better Efficacy and Favorable Safety and Tolerability Against Investigator‐Selected Tyrosine Kinase Inhibitors in East Asian Patients With Newly Diagnosed Chronic Myeloid Leukemia: Results From a Subgroup Analysis of the Pivotal ASC4FIRST Study |
| title_sort | asciminib provides better efficacy and favorable safety and tolerability against investigator‐selected tyrosine kinase inhibitors in east asian patients with newly diagnosed chronic myeloid leukemia: results from a subgroup analysis of the pivotal asc4first study |
| topic | Oncology General Oncology |
| url | https://onlinelibrary.wiley.com/doi/10.1002/cam4.72019?af=R |